Ultragenyx Pharmaceutical Inc

Common Name

Ultragenyx Pharmaceutical

Country

United States

Sector

Healthcare

Industry

Biotechnology

Employees

1,294

Ticker

RARE

Exchange

NASDAQ/NGS

Website

www.ultragenyx.com

Description

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company that focuses on the development and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases. The com... Show more

Financial Statements of Ultragenyx Pharmaceutical

Below are the financial statements of Ultragenyx Pharmaceutical, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.

Income Statement (as reported) Balance Sheet (as reported)

All figures in millions of USD	2024	2023
Current assets	—	—
Cash and cash equivalents	173.73^a	213.58^a
Marketable debt securities	436.3^a	363.63^a
Accounts receivable, net	121.8^a	73.39^a
Inventory	45.01^a	33.97^a
Prepaid expenses and other assets	40.29^a	47.62^a
Total current assets	817.12^a	732.18^a
Assets	—	—
Property, plant, and equipment, net	265.93^a	290.57^a
Marketable debt securities	135^a	199.9^a
Intangible assets, net	178.31^a	166.27^a
Goodwill	44.41^a	44.41^a
Other assets	62.68^a	57.69^a
Total assets	1,503.46^a	1,491.01^a
Current liabilities	—	—
Accounts payable	38.76^a	42.11^a
Accrued liabilities	240.97^a	196.49^a
Lease liabilities	10.3^a	12.6^a
Liabilities for sales of future royalties	49.85^a	29.24^a
Other liabilities	4.28^a	0^a
Total current liabilities	344.15^a	280.44^a
Liabilities and stockholders' equity	—	—
Lease liabilities	30.04^a	30.57^a
Deferred tax liabilities	30.06^a	30.06^a
Liabilities for sales of future royalties	819.82^a	862.33^a
Other liabilities	17.08^a	12.21^a
Total liabilities	1,241.16^a	1,215.6^a
Noncontrolling interest	7^a	0^a
Stockholders’ equity	—	—
Preferred stock	0^a	0^a
Common stock	0.09^a	0.08^a
Treasury stock, at cost	-3.59^a	-0.43^a
Deferred compensation obligation	3.59^a	0.43^a
Additional paid-in capital	4,212.69^a	3,662.35^a
Accumulated other comprehensive (loss) income	-0.64^a	0.65^a
Accumulated deficit	-3,956.84^a	-3,387.66^a
Total stockholders’ equity	255.3^a	275.41^a
Total liabilities, noncontrolling interest and stockholders’ equity	1,503.46^a	1,491.01^a

Verified Sources Behind Ultragenyx Pharmaceutical’s Financial Fundamentals Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Ultragenyx Pharmaceutical’s data sources below and access millions more through our Disclosure Search.

a. Ultragenyx Pharmaceutical's 10-K 2024

Trace every data point back to Ultragenyx Pharmaceutical’s disclosures

Sign up for Tracenable and access millions of corporate disclosures, including annual reports and sustainability filings from global companies, completely free of charge.

Real-Time & Standardized Financials

Access Standardized Financial Statements within Minutes of Disclosure

At Tracenable, we're exploring the launch of real-time standardized financial datafeeds and APIs covering global equities. Unlike limited and inconsistent XBRL parsing, our approach aims to deliver clean, comparable, and fully traceable data seconds after publication.

Could this solution support your investment or analytical workflows?

Explore Peer Companies

Welcome Back to Tracenable

Sign in to your account

Ultragenyx Pharmaceutical Inc

Financial Statements of Ultragenyx Pharmaceutical

Verified Sources Behind Ultragenyx Pharmaceutical’s Financial Fundamentals Data

Access Standardized Financial Statements within Minutes of Disclosure

Explore Peer Companies

TG Therapeutics Inc

SpringWorks Therapeutics Inc

ADMA Biologics Inc

Axsome Therapeutics Inc

Iovance Biotherapeutics Inc

Insmed Inc